title: Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin.
abstract: Despite the theoretical risk of serotonin toxicity (ST) with linezolid, "real-world" clinical evaluations of the risk of ST in patients receiving linezolid have been limited to case reports and noncomparator studies. An observational, matched-cohort study was conducted to evaluate the risk of ST among hospitalized patients who received linezolid or vancomycin at the Upstate New York Veterans Affairs Healthcare Network (Veterans Integrated Service Network 2 [VISN-2]). Matching criteria included VISN-2 hospital, hospital ward, prior hospital length of stay, age, and baseline platelet counts. The patients' electronic medical records were evaluated for symptoms consistent with ST and the Hunter serotonin toxicity criteria (HSTC) using an intensive, natural word search algorithm. The study included 251 matched pairs. Demographics and comorbidities were similar between groups. Over half of the study population received at least one concurrent medication with serotonergic activity. Receipt of agents with serotonergic activity was more pronounced in the vancomycin group, and the higher frequency was due to concomitant antihistamine and antiemetic use. Antidepressant use, including selective serotonin reuptake inhibitors (SSRIs), was similar between groups. No patients in either group were found to meet the criteria using the word search algorithm for ST. Fewer linezolid patients than vancomycin patients met the HSTC overall (3.2% versus 8.8%) and when stratified by receipt of a concurrent serotonergic agent (4.3% versus 12.4%). Of the patients meeting the HSTC, most had past or present comorbidities that may have contributed to or overlapped the HSTC. This study of hospitalized patients revealed comparably low frequencies of adverse events potentially related to ST among patients who received linezolid or vancomycin.
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Lodise
authors.forename: N
authors.initials: N
authors.lastname: Patel
authors.forename: A
authors.initials: A
authors.lastname: Rivera
authors.forename: L
authors.initials: L
authors.lastname: Tristani
authors.forename: V
authors.initials: V
authors.lastname: Lazariu
authors.forename: H
authors.initials: H
authors.lastname: Vandewall
authors.forename: L A
authors.initials: LA
authors.lastname: McNutt
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015331:Cohort Studies; D004347:Drug Interactions; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D009518:New York; D023303:Oxazolidinones / Q000627:therapeutic use*; D012701:Serotonin / Q000097:blood*; D014640:Vancomycin / Q000627:therapeutic use*; D014728:Veterans; D058014:Veterans Health
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D000932:Antiemetics; D006633:Histamine Antagonists; D023303:Oxazolidinones; D012701:Serotonin; D014640:Vancomycin; D000069349:Linezolid
references.citation: N Engl J Med. 2005 Mar 17;352(11):1112-20
references.pmid: 15784664
references.citation: Clin Infect Dis. 2003 Jun 1;36(11):1418-23
references.pmid: 12766837
references.citation: Clin Infect Dis. 2011 Feb 1;52(3):285-92
references.pmid: 21217178
references.citation: Am J Psychiatry. 1991 Jun;148(6):705-13
references.pmid: 2035713
references.citation: Clin Infect Dis. 2003 Jul 1;37(1):e8-11
references.pmid: 12830431
references.citation: Prim Care Companion J Clin Psychiatry. 2009;11(6):353-6
references.pmid: 20098528
references.citation: Clin Infect Dis. 2003 May 1;36(9):1197
references.pmid: 12715317
references.citation: Clin Infect Dis. 2006 Jun 1;42(11):1578-83
references.pmid: 16652315
references.citation: J Am Med Dir Assoc. 2004 Mar-Apr;5(2):111-3
references.pmid: 14984623
references.citation: Psychosomatics. 2005 May-Jun;46(3):274-5
references.pmid: 15883150
references.citation: Arch Intern Med. 2002 Oct 28;162(19):2229-35
references.pmid: 12390067
references.citation: Crit Care Med. 1985 Oct;13(10):818-29
references.pmid: 3928249
references.citation: Clin Infect Dis. 2002 Jun 15;34(12):1651-2
references.pmid: 12032904
references.citation: J Antimicrob Chemother. 2012 Feb;67(2):494-502
references.pmid: 22139199
references.citation: J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):790
references.pmid: 15213578
references.citation: Ann Pharmacother. 2005 May;39(5):956-61
references.pmid: 15827071
references.citation: J Clin Psychiatry. 2003 May;64(5):609-11
references.pmid: 12755668
references.citation: N Engl J Med. 2005 Jun 9;352(23):2454-6; author reply 2454-6
references.pmid: 15948272
references.citation: Antimicrob Agents Chemother. 2013 Dec;57(12):5901-11
references.pmid: 24041888
references.citation: J Clin Epidemiol. 2006 Dec;59(12):1266-73
references.pmid: 17098569
references.citation: Clin Infect Dis. 2006 Jul 15;43(2):180-7
references.pmid: 16779744
references.citation: Mayo Clin Proc. 2006 Mar;81(3):330-4
references.pmid: 16529136
references.citation: Psychosomatics. 2001 Sep-Oct;42(5):432-4
references.pmid: 11739912
references.citation: J Antimicrob Chemother. 2004 Jul;54(1):289-90
references.pmid: 15140859
references.citation: Am J Epidemiol. 2008 Mar 1;167(5):546-52
references.pmid: 18079131